Ranihexal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ranihexal

Property Description
Active ingredient Ranitidine
Pharmacological class Histamine H2-receptor antagonist (H2-blocker)
Manufacturer Sandoz (Historically associated brand)
Typical Use Reducing stomach acid for ulcers, GERD (Historically)
Current Status Withdrawn from many global markets due to safety concerns

Ranihexal is a pharmaceutical product whose active ingredient is ranitidine. This compound belongs to a class of medications known as histamine H2-receptor antagonists, or H2-blockers. These drugs are clinically recognized for their ability to significantly reduce the amount of acid produced and secreted by the stomach, achieving this by blocking the action of histamine at specific receptors on the gastric parietal cells.

Historically, ranitidine was widely used globally for treating conditions caused by excessive stomach acid. Its main indications included the short-term treatment of active duodenal and gastric ulcers, and the management of gastroesophageal reflux disease (GERD). Pharmacological studies confirm its role in promoting the healing of ulcers and preventing their recurrence.

A critical factor distinguishing ranitidine from other acid reducers is its current status. Due to concerns regarding a potentially cancer-causing impurity, N-nitrosodimethylamine (NDMA), the immediate withdrawal of all ranitidine products from the market was requested in April 2020. This decision was based on evidence that the NDMA impurity could increase over time, especially when stored at higher than room temperatures. Patients should consult their healthcare provider about transitioning to alternative, approved treatments for acid-related conditions.

Regulatory References

  1. Ranitidine (LiverTox)

What side effects are possible with Ranihexal?

Official Safety Profile and Limitations

The safety profile for the active ingredient ranitidine is characterized by officially classified adverse reactions and a major regulatory safety constraint that led to its global withdrawal. Adverse events are grouped by System-Organ Class (SOC) and documented by frequency.

Frequency-Classified Adverse Reactions

Classification Examples of Reactions
Common Headache.
Rare Serious hypersensitivity (anaphylaxis), severe blood disorders (e.g., thrombocytopenia), severe skin reactions, and hepatobiliary disorders (e.g., hepatitis, liver failure).

Serious Adverse Reactions and Constraints

Serious reactions officially documented include hepatotoxicity (liver injury) and life-threatening anaphylaxis.

A critical, administration-agnostic constraint is the established risk related to the impurity N-nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen, and regulatory bodies, including the U.S. Food and Drug Administration (FDA), found that its levels could increase over time, particularly under higher storage temperatures. This time- and temperature-related instability ultimately led to the withdrawal of all ranitidine products from the market.

Population-Specific Safety Notes

Official labels note that elderly or severely ill patients may have increased susceptibility to Central Nervous System effects, such as reversible mental confusion and hallucinations. Caution is also required in patients with renal impairment due to the drug's excretion pathway. Furthermore, symptomatic relief provided by the medicine does not preclude the presence of a gastric malignancy, a safety note included in official prescribing information.

Overdose and Emergency Response

Documented Overdose Manifestations

Overdose of the active substance in Ranihexal is officially documented to involve specific clinical manifestations, primarily affecting the neurological and cardiovascular systems. These signs may include confusion, drowsiness, agitation, hallucinations, and slurred speech. Cardiovascular effects can manifest as an abnormal heartbeat (slow, fast, or irregular) and low blood pressure. Other documented presentations include nausea, vomiting, and diarrhea.

Severe Outcomes and Mandatory Action

Regulatory labeling explicitly identifies severe or life-threatening outcomes that require immediate medical intervention. These include signs of serious hypersensitivity reactions (such as collapse or difficulty breathing), seizure, and evidence of hepatic effects (such as jaundice or dark urine). Official government guidance mandates that individuals seek immediate emergency medical attention or contact a Poison Control Center immediately, even if no symptoms are apparent. For individuals who have collapsed or have trouble breathing, emergency services must be called right away.

Management and Specific Risk

Treatment for ranitidine overdose is limited to symptomatic and supportive management, as regulatory documents confirm that no specific antidote is known. Furthermore, caution and potential dosage adjustment are noted for patients with impaired renal function due to the drug's excretion pathway, which increases the potential for drug accumulation and subsequent overdose effects.

Therapeutic Uses of Ranihexal

Ranihexal is applied across domains where additional symptomatic support is needed to address issues caused by symptoms related to systemic imbalance. It is commonly used to help with symptoms related to physical discomfort in the upper digestive tract, such as heartburn and acid indigestion.

The main uses of this medication are relevant for easing the symptoms of conditions characterized by periods of heightened symptoms. These conditions include Gastro-Oesophageal Reflux Disease (GORD/GERD), duodenal or benign gastric ulcers, and conditions involving inflammatory or irritative processes, such as Zollinger-Ellison syndrome. By easing the overall acid load, Ranihexal supports the patient during difficult episodes and may assist with maintaining functional stability in scenarios where symptoms become temporarily overwhelming.

“This provides support that helps ease the overall symptom burden in conditions where functional stability becomes affected.”

It is considered relevant when supportive symptom management is appropriate, and contributes to improved comfort during symptomatic periods.

Focus: Symptom Management for Heartburn & Acid Indigestion

Eligibility and Restrictions for Use

The use of Ranihexal (ranitidine) is governed by official regulatory constraints, with the primary factor being the mandatory market withdrawal of the product in many global regions, including the U.S. and the E.U. This action, taken by authorities like the FDA and EMA, was due to the potential for N-nitrosodimethylamine (NDMA)—a probable human carcinogen—to increase to unacceptable levels over time and with exposure to heat.

Populations Prohibited from Use (Contraindications)

Official labeling mandates that ranitidine must not be used in patients with:

  • A known hypersensitivity or allergic reaction to ranitidine or any ingredient in the formulation.
  • A history of acute porphyria, as the drug may precipitate an attack of this condition.

Restricted and Conditional Eligibility

Certain populations are eligible for use only under strict conditions or caution, as defined by regulatory documents:

  • Renal Impairment: Patients with impaired kidney function (renal impairment) require a mandatory dose reduction to prevent drug accumulation.
  • Pregnancy and Lactation: Use is not recommended during pregnancy or breastfeeding unless deemed essential by a healthcare professional, as the drug crosses the placenta and is secreted into breast milk.
  • Age Groups: Use is generally not recommended for children under 12 years of age for most standard indications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ranihexal (ranitidine) may interact with a range of medicinal products, primarily by altering stomach acidity or interfering with the elimination of co-administered drugs. The primary mechanism of interaction involves the increase in gastric pH (reduced acidity), which can significantly affect the absorption of certain medicines.

Clinically Relevant Interactions

  • Medicines Requiring Acidic Environment: The exposure and effectiveness of drugs that require an acidic stomach for proper absorption, such as some antivirals (e.g., atazanavir, delavirdine) and certain azole antifungals (e.g., ketoconazole) or tyrosine kinase inhibitors (e.g., gefitinib, erlotinib), may be reduced when co-administered.
  • Anticoagulants: Close monitoring of coagulation is necessary when ranitidine is used concurrently with oral anticoagulants (e.g., warfarin), due to reports of altered prothrombin time.
  • Renal Elimination Competition: Ranitidine may reduce the kidney's elimination of some drugs, such as procainamide. This can lead to increased plasma levels of the co-administered drug, particularly in patients receiving high doses or those with existing kidney impairment.
  • Sedating Agents: Increased exposure of certain benzodiazepines (e.g., midazolam, triazolam) may occur, requiring observation for enhanced or prolonged sedation.
  • Acid-Reducing Agents: High-dose sucralfate may decrease ranitidine absorption, an effect mitigated by spacing administration by at least two hours. Chronic use of H2-receptor antagonists may also impair the absorption of Vitamin B12.

Mechanism of Action

How Ranihexal Works


Targeted H2 Receptor Antagonism

Ranihexal (ranitidine) acts by engaging in competitive, reversible antagonism of the Histamine H2 receptors (HRH2), which serve as key molecular targets on the gastric parietal cells. This interaction interrupts the initial signaling step where the natural chemical mediator, histamine, would otherwise activate the acid-producing machinery.


Modulation of Gastric Acid Secretion Cascade

The blockade of the H2 receptor modifies the entire gastric acid secretion pathway, specifically by preventing the histamine-mediated Gs protein cascade that activates the H^+/ K^+-ATPase (Proton Pump). This suppression of the molecular sequence leads directly to the resulting physiological effect: a reduction in the volume and concentration of secreted hydrogen ions ( H^+), thereby raising the stomach's pH.


Constraint by Alternative Signaling Pathways

A mechanistic limitation of Ranihexal is its selectivity; it only blocks the histamine pathway. It does not modulate the parallel signals originating from gastrin or acetylcholine which also stimulate acid secretion. Consequently, its acid-suppressing mechanism is less effective when these alternative mediators dominate, such as during the peak response to a meal.

Dosage and Administration Information

How to use Ranihexal: Official Administration Guidelines

This section describes the official, label-based instructions for the administration and dosing of ranitidine, the active ingredient in Ranihexal.

Administration Aspect Official Instruction
Routes & Forms Approved for Oral (tablets, solutions) and Parenteral (intravenous [IV] or intramuscular [IM] injection) administration.
Standard Adult Dose Acute Treatment: 150 mg twice daily or 300 mg once daily at bedtime. Maintenance: 150 mg once daily at bedtime.
Dosing Frequency Ranges from once daily (q.d.) to four times daily (q.i.d.) for oral forms, and every 6 to 8 hours for parenteral forms.
Timing Relative to Meals For most prescription regimens, oral doses do not need to be timed in relation to meals; they can be taken with or without food.
Renal Adjustment A dose adjustment is required for patients with impaired renal function (creatinine clearance < 50 mL/min); the dose is typically reduced to 150 mg every 24 hours.
Administration Requirements IV bolus injections must be administered slowly over a minimum of five minutes. Effervescent forms must be fully dissolved in a glass of water before being consumed.
Course Duration The maximum duration for self-treatment (OTC use) is 14 days. Treatment courses for acute ulcers typically range from 4 to 8 weeks, with maintenance therapy possibly extending up to one year.

The official instructions establish a structured protocol that dictates the physical route of administration, the required dose magnitude, and the time-based regimen (e.g., twice daily or nightly). This framework is supplemented by rules governing preparation, such as dissolving effervescent forms, and mandatory dose modifications for specific patient populations, such as those with reduced kidney function.

Recent Clinical Evidence

Research evidence / Overview of studies for Ranihexal

Ranitidine, the active ingredient in Ranihexal, was studied for a range of conditions related to stomach acid production. The existing evidence base consists primarily of historical Randomized Controlled Trials (RCTs) and long-term observational studies. This overview describes what the research examined and the limitations noted by researchers, without offering any clinical guidance or recommendations.


Evidence for Use in Ulcer Healing and Prevention

Studies examined ranitidine’s role in the management of active duodenal and benign gastric ulcers. These studies tracked outcomes such as the status of ulceration confirmed by endoscopy and the frequency of recurrence. Findings describe patterns observed in the studies regarding the status of ulceration and how symptoms evolved for patients over time. Research documented limitations when comparing ranitidine to newer drug classes used for acid reduction. Evidence is limited concerning long-term outcomes for major complications in specific patient groups, and this remains a continued focus of research in the broader field.


Evidence for Managing Heartburn and Acid Reflux (GERD)

Short-term clinical trials investigated ranitidine’s application in managing symptoms associated with Gastroesophageal Reflux Disease (GERD). Research examined how symptoms evolved in adult populations experiencing frequent heartburn, as well as those in specific trials involving children and infants. Studies reported measurements that tracked changes in the frequency and severity of heartburn over defined assessment periods. Trials also documented patterns related to the consumption of antacid tablets by the participants.


Research Gaps and Areas of Uncertainty

Evidence is limited in areas concerning direct comparisons with newer acid-reducing drug classes; findings were mixed, and some comparative data documented differences in healing endpoints. For the pediatric populations, follow-up durations were limited (e.g., two weeks in some comparative trials). Consequently, there is limited information for long-term outcomes regarding the use of ranitidine in these younger age groups. Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain—about this medicine.

Key Studies & References

  1. Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES)
  2. Ranitidine use in pediatrics: current evidence-based review and recommendations (Special Population Review)
  3. Comparison of Hypoallergenic Diet vs. Ranitidine in Treatment of Gastroesophageal Reflux Disease of Infants: A Randomized Clinical Trial

Frequently Asked Questions (FAQ)

Common questions about Ranihexal (FAQ)

Q: How quickly should I expect Ranihexal to start working for my heartburn?

According to official product information, when taken orally, ranitidine generally begins to provide relief from heartburn symptoms relatively quickly. Studies have shown that patients can experience a reduction in symptoms as fast as 55 to 65 minutes after taking a single dose.


Q: What conditions besides heartburn is Ranihexal used to treat?

Regulatory documents indicate that ranitidine is used for more than just heartburn associated with GERD (Gastroesophageal Reflux Disease). It is also used for the short-term treatment of active duodenal and gastric ulcers, and for managing conditions where the stomach produces an excessive amount of acid, such as Zollinger-Ellison syndrome.


Q: How long does the acid-reducing effect of Ranihexal typically last?

Official pharmacological data indicates that the therapeutic effect of a single oral dose of ranitidine, the active ingredient in Ranihexal, typically lasts between 4 to 10 hours. This duration helps inform the appropriate dosing frequency used for various medical conditions.


Q: Can Ranihexal be taken to prevent heartburn, or is it only for relief?

The official over-the-counter (OTC) labeling for ranitidine products supports both uses. It is labeled for the relief of existing heartburn symptoms, and also for the prevention of heartburn when taken just before consuming certain foods or beverages known to trigger symptoms.


Q: What are the most common side effects people report when taking Ranihexal?

Based on official adverse reaction reports, the most common side effects are generally mild. These frequently include headache, constipation, diarrhea, and abdominal discomfort or pain. Concerns about severe or persistent symptoms should be raised with a healthcare professional.


Q: Is it normal to feel a headache or dizziness after taking Ranihexal?

Official safety data lists headache as a common side effect of ranitidine use. Dizziness, however, is reported less frequently. Official documentation indicates that elderly or severely ill patients may experience an increased susceptibility to central nervous system effects.


Q: What happens if I take Ranihexal with alcohol?

Clinical studies reviewed by regulatory bodies suggest that ranitidine is not thought to significantly change the effects of alcohol on the body or alter blood alcohol concentrations.


Q: Does Ranihexal interact with common over-the-counter pain relievers like ibuprofen or aspirin?

The official safety label does not list a major pharmacokinetic interaction with Ibuprofen, but ranitidine's use alongside NSAIDs (like Ibuprofen or Aspirin) should be considered carefully. The potential for an increased risk of gastrointestinal bleeding or other complications that can occur with NSAIDs should be considered when these drugs are taken together.


Q: Are there certain supplements or vitamins that should not be taken with Ranihexal?

Ranitidine works by lowering stomach acid, which can affect how certain substances are absorbed. Official information indicates that supplements, like some forms of iron or calcium, that require a highly acidic environment to be absorbed properly may be affected. Chronic use may also impair the absorption of Vitamin B12.


Q: Can Ranihexal be taken safely with other acid reflux medications, like antacids?

Regulatory guidance suggests that ranitidine can generally be taken with standard antacids. However, to ensure optimal absorption of both medications, it is recommended to maintain a time separation for potent antacids. For instance, the label for the interaction with sucralfate recommends spacing doses by at least two hours.


Q: Can children or teenagers use Ranihexal?

Official labeling generally advises against self-treatment (OTC use) of ranitidine in children under the age of 12. For individuals aged 12 and above, and for specific conditions in younger children, use may be considered under the guidance of a healthcare professional.


Q: Is Ranihexal safe for elderly patients to take?

Official product information notes that older adults may be more sensitive to the effects of ranitidine, especially Central Nervous System side effects like confusion. Use in this population may necessitate adjustments in the dosage regimen based on factors like kidney function.


Q: Does Ranihexal work better for nocturnal (night-time) acid reflux?

Clinical studies suggest that ranitidine is particularly effective at suppressing basal and nocturnal acid secretion, which is the acid produced while the stomach is resting or during the night. This pharmacological effect supports its frequent recommendation for a once-daily dose taken at bedtime.


Q: How long is the typical treatment course for a duodenal ulcer using Ranihexal?

According to official prescribing guidelines, treatment courses for acute ulcers, including duodenal ulcers, typically range from 4 to 8 weeks. The specific duration of treatment is determined by a healthcare provider based on the individual's condition.


Q: Are there any signs that Ranihexal is not working effectively for my symptoms?

Official labeling states that if heartburn symptoms worsen, do not improve, or if the medication is needed for more than 14 days of continuous self-treatment, the issue should be evaluated by a healthcare professional.


Q: Is Ranihexal a generic medicine, or is it a specific brand name?

Ranihexal is a specific brand name for a product. Its active ingredient is called ranitidine, which is the common, generic name for the pharmaceutical compound. Ranitidine is the name under which the drug is generally known and regulated.


Q: Are there any lifestyle changes that make Ranihexal more effective?

Official drug facts often advise that ranitidine's effectiveness can be supported by certain lifestyle adjustments. These can include avoiding smoking, reducing alcohol intake, and making dietary changes, such as avoiding foods or beverages known to trigger reflux symptoms.


Q: Can Ranihexal affect my mood or cause mental confusion?

Regulatory documents mention that rare cases of adverse reactions affecting the mind have been reported. These include reversible mental confusion, agitation, depression, and hallucinations, which are primarily seen in severely ill or elderly patients.


Q: Is a metallic or strange taste in my mouth a potential side effect of Ranihexal?

Official adverse reaction reports have occasionally included general taste disturbances as a reported side effect of ranitidine products. While a specific 'metallic taste' is not universally listed, general changes to taste can be a rare adverse reaction.


Q: What is Zollinger-Ellison syndrome, and how does Ranihexal help with it?

Zollinger-Ellison syndrome is a rare condition that causes the digestive system to produce pathologically high levels of gastric acid. Ranitidine is indicated for this syndrome because it helps by directly and significantly decreasing this excessive acid secretion, managing the primary symptom of the disorder.


Q: Does Ranihexal have any effect on blood pressure?

Cardiovascular adverse reactions are rare, but official labeling reports that changes in heart rhythm, such as bradycardia (slow heart rate) or tachycardia (fast heart rate), have been reported. Such changes in heart function can sometimes have secondary effects on blood pressure.


Q: Why do some ranitidine products come in effervescent tablet form?

The effervescent tablet is a specific pharmaceutical formulation that is intended to be fully dissolved in a glass of water before being consumed. This dosage form offers an alternative route of administration for patients, allowing the medicine to be taken as a solution.

How should Ranihexal be stored and disposed of?

How to Store and Dispose of Ranihexal (Ranitidine)

Official labeling historically required ranitidine to be stored at controlled room temperature, specifically 20 to 25 C (68 to 77 F), protected from light, excess moisture, and excess heat. The medication must be kept in its tightly closed, original container and stored out of the sight and reach of children.

The storage profile is connected to product stability: studies confirm the impurity NDMA increases over time, accelerated significantly by storage at temperatures above this range.

Due to this stability concern, the U.S. Food and Drug Administration (FDA) issued a mandatory instruction to stop using all ranitidine products. The official disposal method is household trash, specifically by mixing the product with an unappealing substance (e.g., dirt, coffee grounds) and sealing it in a plastic bag. The product must not be returned to a drug take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ranihexal found in:

A-Z Index: